搜索
Bioatla Inc
BCAB添加自选
4.270USD
-0.100-2.29%
收盘 05/15, 16:00（美东）报价延迟15分钟
5.42M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.29%
5天
-11.78%
1月
-13.03%
6月
+440.51%
今年开始到现在
+652.16%
1年
+966.97%
TradingKey Bioatla Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Bioatla Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名67/382位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价10.00。中期看，股价处于上升通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Bioatla Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Bioatla Inc亮点
亮点风险
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
业绩增长期
公司处于发展阶段，最新年度总收入2.00M美元
估值高估
公司最新PE估值-0.02，处于3年历史高位
机构减仓
最新机构持股326.93K股，环比减少54.59%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值14.14K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.97
分析师目标
根据
1
位分析师
强力买入
评级
10.000
目标均价
+6427.42%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Bioatla Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Bioatla Inc简介
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
公司代码BCAB
公司Bioatla Inc
CEOShort (Jay M)
网址https://www.bioatla.com/
相关品种
